<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02029001</url>
  </required_header>
  <id_info>
    <org_study_id>ET12-081</org_study_id>
    <secondary_id>2012-004510-34</secondary_id>
    <nct_id>NCT02029001</nct_id>
  </id_info>
  <brief_title>Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: My Own Specific Treatment</brief_title>
  <acronym>MOST plus</acronym>
  <official_title>A Two-period, Multicenter, Randomized, Open-label, Phase II Study Evaluating the Clinical Benefit of a Maintenance Treatment Targeting Tumor Molecular Alterations in Patients With Progressive Locally-advanced or Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Leon Berard</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Leon Berard</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The MOST Plus study is a two-period phase II clinical trial, conducted in patients with all
      types of progressive solid tumors after at least 1 prior systemic treatment regimen for
      advanced disease (in the absence of a validated second line therapy).

      The main goal of this study is to evaluate for these patients the clinical benefit of a
      maintenance treatment in patients with stable disease after induction treatment with a
      selected therapy (Molecular Targeted Therapy (MTT) or Immunotherapy (IT)).

      For MTT, the first period of this trial (induction period) will enable to establish whether
      the identification of genomic alterations in genes encoding for &quot;actionable&quot; targets in the
      tumor cells, regardless of the histological subtype, can be used to select efficient
      treatment targeting the pathway activated by the mutation.

      For Immunotherapy, induction period with durvalumab + tremelimumab is expected to be an
      innovative therapy for an efficient tumor control and may allow to identify types of cancer
      or molecular types of cancer that are more receptive to immunotherapy.

      For all treatments, the second period (maintenance period) will use a randomized design to
      evaluate the clinical benefit of a maintenance treatment with this targeted therapy selected
      based on tumor molecular profile in patients with stable disease.

      Each patient enrolled will receive the matching targeted therapy during 12 weeks (MTT) or 24
      weeks (IT). At the end of this induction period:

        -  patients with a tumor response will continue the targeted therapy,

        -  patients in progression will discontinue the targeted therapy and will be withdrawn from
           study and oriented towards standard treatments

        -  patients with a stable disease at 12 weeks (MTT) or 24 weeks (IT) will be randomized in
           order to determine if they continue or stop the therapy.

      About 80 patients will be treated in each of the 5 MTT treatment groups opened to enrollment
      and 125 patients will be treated in IT treatment groups , each group corresponding to an
      available targeted therapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 2014</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Induction Progression-Free Rate after induction treatment</measure>
    <time_frame>12 weeks for MTT or 24 weeks for IT after initiation of study treatment</time_frame>
    <description>The proportion of patients without documented disease progression within induction period (the first 12 weeks of study treatment or 24 weeks for IT).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-Free Survival (PFS) in both study arms after randomization</measure>
    <time_frame>tumor assessment every 2 to 3 months until up to 36 months after treatment start or patient's withdrawal</time_frame>
    <description>Measured from the date of randomization until the date of event defined as the first documented progression or death from any cause. Patients with no event at the time of the analysis will be censored at the date of the last available tumor assessment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Over the induction period</time_frame>
    <description>Proportion of patients with complete response (CR) or partial response (PR) as best overall response over the induction period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>from the date of randomization to the date of death from any cause</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's quality of life score (QLQ-C30) in both arms after randomization</measure>
    <time_frame>At randomization (week 12), week 28 and end of study for patient (week 136 or premature study withdrawal)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessment</measure>
    <time_frame>Over the whole study</time_frame>
    <description>Type, frequency, seriousness and causality of adverse events reported from treatment initiation based on the common toxicity criteria grade (NCI CTC-AE-V4.03)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Duration of response (exploratory outcome)</measure>
    <time_frame>Over the whole study</time_frame>
    <description>Measured from the time of first documented response (CR or PR) until the first documented disease progression or death due to underlying cancer, and censored at the date of the last available tumor assessment</description>
  </other_outcome>
  <other_outcome>
    <measure>Medico-economic evaluation: cost analysis and cost-effectiveness analysis</measure>
    <time_frame>From randomization until patient's end of study</time_frame>
    <description>Incremental cost-effectiveness ratios (ICERs) will be expressed as:
the cost per life year gained;
the cost per progression-free year gained.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">560</enrollment>
  <condition>Malignant Solid Neoplasms</condition>
  <arm_group>
    <arm_group_label>Arm A: Maintenance treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will continue targeted treatment matching the molecular alterations identified in their tumor for a maximum of 136 weeks starting from the date of patient's first study drug intake following inclusion. In case of on-treatment disease progression, the patient will permanently discontinue treatment and will be withdrawn from study.
Targeted treatments available in the study are: nilotinib, everolimus, sorafenib, lapatinib, pazopanib, olaparib, durvalumab + tremelimumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B:Interruption of targeted treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Targeted treatment received during induction period will be discontinued until a first documented off-treatment disease progression occurs. At progression, treatment reintroduction may be proposed to the patient (left at the investigator's appreciation, and upon patient approval) and treatment may be continued until on-treatment disease progression, unacceptable toxicity or for a maximum of 136 weeks from the date of patient's first study drug intake following inclusion. If the investigator considers that the treatment cannot be safely reintroduced (regarding patient's condition and/or laboratory results), the patient will be withdrawn from study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nilotinib (400 mg BID)</intervention_name>
    <description>Patient with advanced pigmented villonodular synovitis and tumors with mutations of ABL1, KIT, PDGFRA, PDGFRB, DDR1, DDR2, CSF1R, or amplification/translocation of the genes and/or of the ligands.</description>
    <arm_group_label>Arm A: Maintenance treatment</arm_group_label>
    <other_name>Open cohort</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus (10 mg QD)</intervention_name>
    <description>Patients whose tumor harbors mutations or amplification of the PIK3CA, PIK3R1, AKT1, AKT2, mTOR, RICTOR, RAPTOR genes, or with TSC1, TSC2 or PTEN loss (defined as complete loss of both gene copies OR loss of one copy + mutation on the other copy or loss of one copy + loss of expression using immunohistochemistry).</description>
    <arm_group_label>Arm A: Maintenance treatment</arm_group_label>
    <other_name>Closed cohort</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib (400 mg BID)</intervention_name>
    <description>Patients whose tumor harbors mutations of VEGFR1-3, PDFGRB, FLT3, BRAF (other than V600 mutations), CRAF, HRAS, KRAS or RET or amplification/translocation of the genes and/or of the ligands.</description>
    <arm_group_label>Arm A: Maintenance treatment</arm_group_label>
    <other_name>Closed cohort</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lapatinib (1500 mg QD)</intervention_name>
    <description>Patients whose tumor harbors mutations or amplifications of HER2</description>
    <arm_group_label>Arm A: Maintenance treatment</arm_group_label>
    <other_name>Closed cohort</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pazopanib (800 mg QD)</intervention_name>
    <description>Patients whose tumor harbors mutations of VEGFR1-3, PDGFRA, PDGFRB or KIT* or amplification /translocation of the genes and/or of the ligands.</description>
    <arm_group_label>Arm A: Maintenance treatment</arm_group_label>
    <other_name>Open cohort</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olaparib (300 mg BID)</intervention_name>
    <description>Mutation BRCA1/2 (somatic and germline) or BRCA like and mutations of HDR pathway genes (RAD51 family gene, PALB2, ATM, etc...); except in prostate or stomach; except for patients eligible to Olaparib's available labels in France.</description>
    <arm_group_label>Arm A: Maintenance treatment</arm_group_label>
    <other_name>Open cohort</other_name>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Durvalumab + Tremelimumab</intervention_name>
    <description>Any molecular types of tumor (which are known to be immunogenic or with high mutation load), except lung, urothelial and head and neck or CNS tumors, or patients who fulfill conditions to receive any other MTT of the MOST Plus study.</description>
    <arm_group_label>Arm A: Maintenance treatment</arm_group_label>
    <other_name>Open cohort</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        I1. Male or female patient ≥ 18 years of age.

        I2. Histologically or cytologically confirmed diagnosis of metastatic or locally advanced
        and unresectable solid tumor of any type, except for Nilotinib cohort: only pigmented
        villonodular synovitis are eligible, not amenable to curative treatment. Concerning
        primitive tumors of the central nervous system (CNS), all histological types of malignant
        tumors (including parenchymal and meningeal tumors) are eligible (except for IT).

        I3. Documented disease progression at the time of study entry.

        I4. At least one prior systemic treatment regimen for locally advanced or metastatic
        disease. Patients who are candidates for a validated second line treatment regimen are not
        eligible for the study. For patients with a primitive CNS tumor, the absence of other
        therapeutic options must be validated by the reference committee for the patient's
        pathology before inclusion. As there is no prior systemic treatment regimen available for
        locally advanced or metastatic PEComa, these tumors are eligible for a MTT treatment in
        first line of their advanced or metastatic disease. No previous treatment by immunotherapy
        is allowed for IT group.

        I5. Patient with measurable disease, defined as at least one lesion that can be accurately
        measured on CT-scan or MRI according to RECIST 1.1.

        I6. A multidisciplinary molecular board must have recommended one of the investigational
        MTT available in the study after review of a tumor molecular profiling previously
        established from a biopsied lesion and/or primitive tumor.

        I7. The MTT recommended by the multidisciplinary molecular board after the review of tumor
        molecular profile is not approved and reimbursed in France for the disease affecting the
        patient.

        I8. Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2.

        I9. Adequate organ system function as assessed by the following minimal laboratory
        requirements :

          -  Absolute neutrophil count (ANC) ≥ 1 x 109/L (for pazopanib and olaparib: ≥ 1.5 x
             109/L)

          -  Platelets ≥ 100 x 109/L

          -  Hemoglobin ≥ 9 g/dL. Transfusion is not allowed within 7 days of screening assessment.
             (For olaparib: Hemoglobin ≥ 10 g/dL. Transfusion is not allowed within 28 days of
             screening assessment, no features suggestive of myelodysplastic syndrome (MDS)/Acute
             myeloid leukemia (AML) on peripheral blood smear within the 28 days)

          -  For pazopanib: activated partial thromboplastin time (aPTT) ≤ 1.2x Upper limit of
             normal (ULN) and prothrombin time (PT) or international normalized ratio (INR) ≤ 1.2x
             ULN; Subjects receiving anticoagulant therapy are eligible if their INR is stable and
             within the recommended range for the desired level of anticoagulation.

          -  Aspartate Aminotransferase (AST) and alanine transaminase (ALT) ≤ 3x ULN in the
             absence of liver metastases (≤ 5x ULN for patients with liver involvement of their
             cancer) and total bilirubin ≤ 1.5x ULN. (for pazopanib: AST and ALT ≤ 2.5x ULN;
             concomitant elevations in bilirubin and AST or ALT above 1x ULN are not permitted; for
             olaparib and IT: AST and ALT ≤ 2.5x ULN in the absence of liver metastases (≤ 5x ULN
             for patients with liver involvement of their cancer) and total bilirubin ≤ 1.5x ULN.).

          -  Serum creatinine ≤ 1.5x ULN or creatinine clearance ≥ 50 mL/min (calculated by
             Cockcroft-Gault formula, or modification of diet in renal disease (MDRD) formula for
             patients older than 65 years) (for pazopanib: creatinine clearance ≥ 30 mL/min; for
             olaparib : creatinine clearance ≥ 51 mL/min; for IT : creatinine clearance ≥ 40 mL/min
             )

          -  For pazopanib: Urine Protein to Creatinine ratio (UPC) &lt;1; if UPC ≥1, 24-hour urine
             protein must be &lt;1g (use of urine dipstick for renal function assessment is not
             acceptable).

          -  Corrected QT (QTc) interval ≤ 450 msecs (≤ 480 msecs if recommended MTT has no known
             effect on QT interval) on screening ECG, within 14 days prior to C1D1 (for olaparib :
             QTc &lt; 470 msec on 2 or more time points within a 24 hour period on screening ECG,
             within 7 days prior to C1D1).

        I10. Life expectancy of at least 4 months.

        I11. Specific toxicities related to any prior anti-cancer therapy must have resolved to
        grade ≤1 except for alopecia, vitiligo and fatigue. Grade 2 neutropenia or anemia is
        accepted.

        I12. Women of childbearing potential must have a negative pregnancy test performed within 3
        days prior to study treatment start. A positive urine test must be confirmed by a serum
        pregnancy test.

        I13. Women of childbearing potential (entering the study after a confirmed menstrual period
        and who have a negative pregnancy test) and men of reproductive potential must agree, if
        sexually active, to use two methods of medically acceptable forms of contraception during
        the study and for at least 8 weeks following the last treatment intake. (for olaparib :
        during the study and for at least 1 month for women and 3 months for men following the last
        treatment intake; for IT : during the study and for at least 3 months following the last
        treatment intake).

        I14. Signed and dated informed consent document indicating that the patient has been
        informed of all the pertinent aspects of the trial prior to enrollment.

        I15. The patient must be affiliated to the French social security system.

        I16. The recommended study treatment must have been approved by the medical staff of the
        Steering committee.

        I17. Patient should be able and willing to comply with study visits and procedures as per
        protocol.

        I18. Patient must fulfill ALL following conditions:

          -  Availability of a pre-treatment sample of primary tumor (only formalin-fixed
             paraffin-embedded (FFPE) block with sufficient material) and presence of at least one
             biopsiable tumor lesion for on-treatment biopsy,

          -  Weight &gt; 50 Kg,

          -  Patient with a maximum of 2 prior lines of treatment at time of C1D1 for their
             metastatic or locally advanced.

        Exclusion Criteria:

        Patients eligible for this study must not meet any of the following criteria:

        E1. Previous treatment in advanced phase with an investigational therapy inhibiting the
        same target proteins as this recommended for the study.

        E2. Any contra-indication to receive the recommended MTT, including known or suspected
        hypersensitivity to compounds of similar chemical or biologic composition as the active
        substance, or to any of the excipients.

        E3. For nilotinib, sorafenib, pazopanib, lapatinib and olaparib: Patient with hypokalemia
        or known history of congenital long QT syndrome (QT interval prolongation).

        E4. Prior malignancy or presence of any other active malignancy. Subjects who have had
        another malignancy and have been disease-free for 5 years, or subjects with a history of
        completely resected non-melanomatous skin carcinoma or successfully treated in situ
        carcinoma are eligible.

        E5. Patient who have had major surgery or trauma within 28 days prior to first dose of
        investigational product. Patient must have recovered from any effects of any major surgery.

        E6. Patient with symptomatic or uncontrolled CNS metastatic involvement of his/her cancer,
        unless the patient have stable neurological function without evidence of CNS progression
        within 12 weeks prior to study entry and does not require treatment with enzyme-inducing
        anticonvulsants or steroids. Patients with a primitive tumor of the CNS are not eligible to
        IT and if one of the following conditions is fulfilled:

          -  Alteration of cognitive functions impeding the patient's comprehension of study and
             the provision of informed consent by the patient himself/herself.

          -  Need for supportive care treatment(s) interfering with study treatment.

        E7. Treatment with any of the following anti-cancer therapies prior to the first dose of
        study treatment: radiation therapy (for olaparib : within 3 weeks or 5 half-lives of a drug
        whichever is longer), surgery or tumor embolization within 14 days prior to the first dose
        of study treatment OR immunotherapy within 28 days (except for IT : patient already treated
        with an immunotherapy are excluded) OR chemotherapy (for olaparib : within 3 weeks or 5
        half-lives of a drug whichever is longer), biologic therapy, investigational therapy or
        hormonal therapy within 14 days or 5 half-lives of a drug (whichever is longer). Palliative
        radiotherapy is authorized only if the irradiated field does not include target lesions.

        E8. Administration of any non-oncologic investigational agent within 30 days or 5
        half-lives (whichever is longer) prior to receiving the first dose of study treatment.

        E9. For oral treatment : Patient with any condition that impairs their ability to swallow
        and retain tablets and may affect the absorption of the investigational product are
        excluded.

        E10. For pazopanib: Clinically significant gastrointestinal abnormalities that may increase
        the risk for gastrointestinal bleeding including, but not limited to:

          -  Active peptic ulcer disease

          -  Known intraluminal metastatic lesion(s) with risk of bleeding

          -  Inflammatory bowel disease or other gastrointestinal conditions with increased risk of
             perforation

          -  History of abdominal fistula, gastrointestinal perforation, or intra abdominal abscess
             within 28 days prior to beginning study treatment.

        E11. For pazopanib and IT: Evidence of active bleeding or bleeding diathesis.

        E12. For pazopanib: Known endobronchial lesions and/or lesions infiltrating major pulmonary
        vessels that increase the risk of pulmonary hemorrhage.

          -  Lesions infiltrating major pulmonary vessels (contiguous tumour and vessels) are
             excluded; however, the presence of a tumor that is touching, but not infiltrating
             (abutting) the vessels is acceptable.

          -  Large protruding endobronchial lesions in the main or lobar bronchi are excluded;
             however, endobronchial lesions in the segmented bronchi are allowed.

          -  Lesions extensively infiltrating the main or lobar bronchi are excluded; however,
             minor infiltrations in the wall of the bronchi are allowed.

        E13. For pazopanib: Recent hemoptysis.

        E14. Any clinically significant and/or uncontrolled medical disease that could compromise
        the patient's ability to tolerate study treatment or would likely interfere with study
        procedures or results. These conditions include but are not limited to:

          -  Active clinically serious bacterial or fungal infection

          -  History of uncontrolled or significant cardiac disease within the past 6 months: left
             ventricular ejection fraction (LVEF) &lt; 50%, congestive cardiac failure, active
             ischemic heart disease, ventricular arrhythmia, myocardial infarction within 1 year,
             unstable angina pectoris, cardiac surgery.

          -  Patients with cerebrovascular accident (including transient ischemic attack),
             pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months
             are not eligible for pazopanib treatment group

          -  Poorly controlled hypertension [for pazopanib: defined as systolic blood pressure
             (SBP) ≥140 mmHg or diastolic blood pressure (DBP) ≥ 90 mmHg]

          -  Severely impaired lung function

          -  Active gastrointestinal tract ulceration

          -  Acute or chronic uncontrolled liver disease, or severe renal disease

          -  Uncontrolled diabetes

          -  Known history of human immunodeficiency virus (HIV) infection, or active viral
             infection (hepatitis B virus (HBV), hepatitis C virus (HCV)) at the time of study
             entry and/or requiring anti-viral therapy, or chronic hepatitis B or C. Detection of
             hepatitis C RNA must be performed before inclusion of patients with a history of HCV
             infection: patients with a positive result are excluded.

          -  History of organ allograft or patient taking immunosuppressive treatment.

        E15. Patient unable or unwilling to discontinue use of prohibited medications for at least
        14 days or 5 half-lives of a drug (whichever is longer) prior to the first dose of study
        drug and for the duration of the study.

        E16. Pregnant or breastfeeding women.

        E17. Patients with any medical, psychological, familial, sociological or geographical
        condition potentially hampering compliance with the study protocol and follow-up schedule
        or evaluations of the study results.

        E18. Patient currently treated with drugs that could interfere with study drugs metabolism
        E19. Patients filling at least one of these criteria are excluded. (Specific to olaparib)

          -  Patients with myelodysplastic syndrome/acute myeloid leukaemia or with features
             suggestive of MDS/AML.

          -  Patients considered a poor medical risk due to a serious, uncontrolled seizures,
             uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled
             infection. Examples include, but are not limited to, uncontrolled ventricular
             arrhythmia, recent myocardial infarction, unstable spinal cord compression , superior
             vena cava syndrome, extensive bilateral lung disease on High-resolution computed
             tomography (HRCT) scan.

          -  Previous allogenic bone marrow transplant or double umbilical cord blood
             transplantation and whole blood transfusions in the last 120 days prior to entry to
             the study (packed red blood cells and platelet transfusions are acceptable) are not
             allowed.

          -  Concomitant use of known strong CYP3A inhibitors or moderate CYP3A inhibitors. The
             required washout period prior to starting olaparib is 2 weeks.

          -  Concomitant use of known strong or moderate CYP3A inducers. The required washout
             period prior to starting olaparib is 5 weeks for enzalutamide or phenobarbital and 3
             weeks for other agents.

          -  Patients eligible for olaparib (Lynparza®) in its approved indication: monotherapy for
             the maintenance treatment of adult patients with platinum sensitive relapsed BRCA
             mutated (germline and/or somatic) high grade serous epithelial ovarian, fallopian
             tube, or primary peritoneal cancer who are in response to platinum based chemotherapy.

          -  Patients with the following cancers: breast or prostate or stomach or ovarian or small
             cell lung cancers.

          -  Whole blood transfusions in the last 120 days prior to entry to the study (packed red
             blood cells and platelet transfusions are acceptable).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Yves BLAY, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Leon Berard</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Yves BLAY, MD</last_name>
    <phone>+33478785126</phone>
    <email>jean-yves.blay@lyon.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Olivier TREDAN, MD</last_name>
    <phone>+33478782828</phone>
    <email>olivier.tredan@lyon.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine ITALIANO</last_name>
      <phone>+335 56 33 33 33</phone>
      <email>a.italiano@bordeaux.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Antoine ITALIANO</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maud TOULMONDE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sophie COUSIN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mathilde CABART</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guilhem ROUBAUD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kevin BOURCIER</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yann GODBERT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xavier DURANDO</last_name>
      <phone>04 73 27 81 31</phone>
      <email>xavier.durando@cjp.fr</email>
    </contact>
    <investigator>
      <last_name>Xavier DURANDO</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre DALLOZ</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne-Françoise DILLIES-LEGRAIN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pascale DUBRAY-LONGERAS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hakim MAHAMMEDI</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie-Ange MOURET-REYNIER</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isabelle VAN PRAAGH DOREAU</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Daniel Hollard</name>
      <address>
        <city>Grenoble</city>
        <zip>38028</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cécile LEYRONNAS</last_name>
      <phone>04 76 70 73 33</phone>
      <email>c.leyronnas@ghm-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Cécile LEYRONNAS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claire GARNIER-TIXIDRE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laurence LANCRY-LECOMTE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jérôme LONG, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christine REBISCHUNG, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Yves BLAY</last_name>
      <phone>+33478785126</phone>
      <email>jean-yves.blay@lyon.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Yves BLAY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Virginie AVRILLON</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas BACHELOT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christophe BERGERON</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre BIRON</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Helen BOYLE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe CASSIER</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrick COMBEMALE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria CHELGHOUM</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Françoise DESSEIGNE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cécile FAURE-CONTER</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jérome FAYETTE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aude FLECHON</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christelle DE LA FOUCHARDIERE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Didier FRAPPAZ</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre GUIBERT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre-Etienne HEUDEL</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eve-Marie NEIDHARDT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maurice PEROL</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isabelle RAY-COQUARD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre SAINTIGNY</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Catherine TERRET</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivier TREDAN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stéphane DEPIL</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olfa DERBEL</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nathalie MARQUES</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe TOUSSAINT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mehdi BRAHMI</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthieu SARABI</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alice BONNEVILLE-LEVARD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nadège CORRADINI</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Louis DOUBLET</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Armelle DUFRESNE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lauriane EBERST</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sylvie NEGRIER</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Katell MICHAUX</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne-Sophie MICHALLET</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juliette REURE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pauline ROCHEFORT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Julien FORESTIER, MD</last_name>
      <phone>+33472119738</phone>
      <email>julien.forestier@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Julien FORESTIER</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Catherine LOMBARD BOHAS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas WALTER</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yann MOLIN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Noura BEN SLAMA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François BERTUCCI</last_name>
      <phone>+334 91 22 35 37</phone>
      <email>bertuccif@ipc.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>François BERTUCCI</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Marc EXTRA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anthony GONCALVES</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gwenaëlle GRAVIS-MESCAM</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne MADROSZYK-FLANDIN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Luc RAOUL</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Delphine PERROT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Magali PROVENSAL</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carole TARPIN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frédéric VIRET</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Louis TASSY</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Antonietta CAPPIELLO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Slimane DERMECHE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Simon LAUNAY</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frederique ROUSSEAU</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicolas MEYER</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Loïc MOUREY</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elisabeth MOYAL</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roxana Maria RADUT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Henri ROCHE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thibaud VALENTIN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sarah ZAHI</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marine GILABERT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Erika LOIR</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Audrey MONNEUR</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pauline REIS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75248</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe LE TOURNEAU, MD</last_name>
      <phone>+33144324672</phone>
      <email>Christophe.letourneau@curie.fr</email>
    </contact>
    <investigator>
      <last_name>Christophe LE TOURNEAU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe BEUZEBOC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>François-Clément BIDARD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bruno BUECHER</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paul-Henri COTTU</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Catherine DANIEL</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Véronique DIERAS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Valérie LAURENCE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alain LIVARTOWSKI</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Yves PIERGA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie ALT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Delphine LOIRAT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie-Paule SABLIN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mustapha ZOUBIR</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francesco RICCI</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emanuela ROMANO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivier COLLARD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Edith BORCOMAN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ségolène HESCOT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nouritza TOROSSIAN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benoit YOU, MD</last_name>
      <phone>+33478864319</phone>
      <email>benoit.you@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Benoit YOU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nathalie BONNIN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gilles FREYER</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Salima HAMIZI</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sophie TARTAS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Véronique TRILLET-LENOIR</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marion CHAUVENET</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Denis MAILLET</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julien PERON</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claire FALANDRY</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivia LE SAUX</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de cancérologie LUCIEN NEUWIRTH</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier COLLARD, MD</last_name>
      <phone>04 77 91 70 34</phone>
      <email>olivier.collard@icloire.fr</email>
    </contact>
    <investigator>
      <last_name>Olivier COLLARD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claire BOSACKI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre FOURNEL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aline GUILLOT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Philippe JACQUIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thierry MURON, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Léa SABAN-ROCHE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos-Alberto GOMEZ-ROCA</last_name>
      <phone>05 31 15 51 01</phone>
      <email>Gomez-roca.carlos@iuct-oncopole.fr</email>
    </contact>
    <investigator>
      <last_name>Carlos-Alberto GOMEZ-ROCA</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christine CHEVREAU</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ewa-Anna COTTURA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Florence DALENC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Pierre DELORD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marion DESLANDRES</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laurence GLADIEFF</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eleonora MAIO D'ESPOSITO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicolas MEYER</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Loïc MOUREY</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elisabeth MOYAL</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Henri ROCHE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thibaud VALENTIN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Iphigénie KORAKIS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Delphine LARRIEU-CIRON</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Damien POUESSEL</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>https://www.cancer-lyrican.fr/</url>
    <description>MOST study is part of the LyRICAN project, click here to access LyRICAN website</description>
  </link>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>January 6, 2014</study_first_submitted>
  <study_first_submitted_qc>January 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2014</study_first_posted>
  <last_update_submitted>July 22, 2019</last_update_submitted>
  <last_update_submitted_qc>July 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Solid tumor</keyword>
  <keyword>Recurrent/metastatic</keyword>
  <keyword>Personalized medicine</keyword>
  <keyword>Genomic alteration</keyword>
  <keyword>Targeted therapy</keyword>
  <keyword>Nilotinib</keyword>
  <keyword>Everolimus</keyword>
  <keyword>Sorafenib</keyword>
  <keyword>Lapatinib</keyword>
  <keyword>Pazopanib</keyword>
  <keyword>Olaparib</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Durvalumab</keyword>
  <keyword>Tremelimumab</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Durvalumab</mesh_term>
    <mesh_term>Lapatinib</mesh_term>
    <mesh_term>Olaparib</mesh_term>
    <mesh_term>Tremelimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

